175153-03-4

Basic information

• Product Name: 4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID
• Synonyms: 4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID;Benzoic acid,4-(2-oxo-1-piperidinyl)-
• CAS NO: 175153-03-4
• Molecular Formula: C₁₂H₁₃NO₃
• Molecular Weight: 219.24
• Mol File: 175153-03-4.mol

Chemical Properties

• Boiling Point: 508.3 °C at 760 mmHg
• Flash Point: 261.2 °C
• Appearance: /
• Density: 1.284 g/cm³
• CAS DataBase Reference: 4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID(175153-03-4)
• EPA Substance Registry System: 4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID(175153-03-4)

Safety Data

• Hazardous Substances Data: 175153-03-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure, which includes a piperidine ring and a benzoic acid group, makes it a valuable building block in the development of new therapeutic agents.
Used in Drug Discovery:
In the field of drug discovery, 4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID is utilized as a potential candidate for the creation of novel drugs. Its specific properties and the presence of functional groups make it a promising starting point for medicinal chemists to explore its potential in treating various diseases and conditions.
Used in Medicinal Chemistry:
4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID is employed as a key component in medicinal chemistry for the design and synthesis of bioactive molecules. Its structural features allow for the development of compounds with specific biological activities, which can be further optimized for therapeutic applications.
Used in Synthesis of Complex Molecules:
As a building block, 4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID is used in the synthesis of more complex organic molecules. Its versatility in chemical reactions enables the creation of a wide range of compounds with diverse applications in various fields, including pharmaceuticals, materials science, and chemical research.
The precise applications and properties of 4-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID are still being explored, and its potential uses may expand as more research is conducted in these areas.

Upstream product

• 1575-61-7 5-Chlorovaleroyl chloride 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 444815-14-9 N-(4-ethoxycarbonylphenyl)-2-piperidone 
• 619-45-4 4-methoxycarbonyl aniline 
• 889129-50-4 4-(5-chloro-pentanoylamino)-benzoic acid methyl ester 
• 619-44-3 methyl 4-iodobenzoate 
• 675-20-7 piperidin-2-one 
• 503614-97-9 methyl 4-(2-oxopiperidin-1-yl)benzoate 

Downstream Products

• 221360-86-7 4-(5-oxo-1,4-diazepan-1-yl)benzoic acid 
• 197446-35-8 (R)-N-[8-(4-Methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-(4-piperidon 1-yl)benzamide 
• 503613-45-4 5-chloro-N-(5-chloropyridin-2-yl)-3-methoxy-2-[4-(2-oxopiperidin-1-yl)benzoylamino]benzamide 
• 503613-37-4 5-chloro-N-(5-chloropyridin-2-yl)-2-({4-[(2-oxopiperidine)-1-yl]benzoyl}amino)benzamide 
• 1394169-65-3 (S)-N-(4-chlorophenyl)-2-(4-(2-oxopiperidin-1-yl)benzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 678179-39-0 3-[4-(2-oxo-piperidin-1-yl)-benzoylamino]-propionic acid methyl ester 

Relevant articles and documents

Ring size changes in the development of class I HDAC inhibitors

Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.

Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors

Factor Xa (fXa) is a crucial player in various thromboembolic disorders. Inhibition of fXa can provide safe and effective antithrombotic effects. In this study, a series of anthranilamide compounds were designed by utilizing structure-based design strategies. Optimization at P1 and P4 groups led to the discovery of compound 16g: a highly potent, selective fXa inhibitor with pronounced in vitro anticoagulant activity. Moreover, 16g also displayed excellent in vivo antithrombotic activity in the rat venous thrombosis (VT) and arteriovenous shunt (AV-SHUNT) models. The bleeding risk evaluation showed that 16g had a safer profile than that of betrixaban at 1 mg/kg and 5 mg/kg dose. Additionally, 16g also exhibited satisfactory PK profiles. Eventually, 16g was selected to investigate its effect on hypoxia-reoxygenation- induced H9C2 cell viability. MTT results showed that H9C2 cell viability can be remarkably alleviated by 16g.

LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

3,4-dibenzamido benzamide derivative, preparation method and application thereof

The invention discloses a 3,4-dibenzamido benzamide derivative (I), wherein R1, R2 and R3 are respectively and individually hydrogen, fluorine, chlorine, bromine, hydroxyl groups, alkoxy groups, amino groups or substituted amino groups. The alkoxy groups

Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties

Introduction of the phenyl piperidinone and phenyl pyridinone P4 moieties in the anthranilamide scaffold led to potent, selective, and orally bioavailable inhibitors of factor Xa. Anthranilamide 28 displayed comparable efficacy to apixaban in the rabbit a

SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa

In the search of Factor Xa (FXa) inhibitors structurally different from the pyrazole-based series, we identified a viable series of enantiopure cis-(1R,2S)-cycloalkyldiamine derivatives as potent and selective inhibitors of FXa. Among them, cyclohexyldiam

Synthesis of a new family of N-aryl lactams active on chemesthesis and taste

A new class of synthetic compounds with chemesthetic activity has been identified. They have been designed ex-novo by structural similarity with known cooling compounds such as menthol, icilin and cyclic ketoenamines. 19 new derivatives have been obtained